STEPHANIE FELUS-HARKER: Open Payments
NPI 1437124336 · LYKENS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$668 in 35 payments from 13 companies in 2025. Trend: 2023 $1,216 · 2024 $1,160 · 2025 $668
Food & beverage: $668
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $95 |
| ABBVIE INC. | 4 | $92 |
| AstraZeneca Pharmaceuticals LP | 5 | $83 |
| GlaxoSmithKline, LLC. | 3 | $71 |
| Dexcom, Inc. | 3 | $68 |
| Lilly USA, LLC | 3 | $55 |
| PFIZER INC. | 3 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Merck Sharp & Dohme LLC | 1 | $24 |
Products named: SHINGRIX, Dexcom G6 Transmitter, QULIPTA, MOUNJARO, Ozempic, AIRSUPRA, CAPLYTA, GEMTESA.
Industry payments across PA — which companies pay providers there.
